BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial-Reference-Cited by-同舟云学术

BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial

Published:2016-07-19 Issue:1 Volume:16 Page:
ISSN:1471-230X
Container-title:BMC Gastroenterology
language:en
Short-container-title:BMC Gastroenterol

Author:

Hegade Vinod S.,Kendrick Stuart F. W.,Dobbins Robert L.,Miller Sam R.,Richards Duncan,Storey James,Dukes George,Gilchrist Kim,Vallow Susan,Alexander Graeme J.,Corrigan Margaret,Hirschfield Gideon M.,Jones David E. J.

Funder

National Institute for Health Research

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12876-016-0481-9.pdf

Reference31 articles.

1. Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis. Semin Liver Dis. 2014;34(3):318–28. doi: 10.1055/s-0034-1383730 . published Online First: Epub Date.

2. Beuers U, Boberg KM, Chapman RW, et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67. doi: 10.1016/j.jhep.2009.04.009 . published Online First: Epub Date.

3. Hegade VS, Mells GF, Beuers U, et al. Patient Experience and Characteristics of Cholestatic Pruritus in the UK-PBC Research Cohort. Hepatology. 2014;60:339A–69. doi: 10.1002/hep.27496 . published Online First: Epub Date.